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Abstract
 
We have previously shown that the obligate intracellular pathogen chlamydia can suppress in-
 
terferon (IFN)-
 
g
 
–inducible major histocompatibility complex (MHC) class II expression in in-
fected cells by degrading upstream stimulation factor (USF)-1. We now report that chlamydia
can also inhibit both constitutive and IFN-
 
g
 
–inducible MHC class I expression in the infected
cells. The inhibition of MHC class I molecule expression correlates well with degradation of
RFX5, an essential downstream transcription factor required for both the constitutive and
IFN-
 
g
 
–inducible MHC class I expression. We further demonstrate that a lactacystin-sensitive
proteasome-like activity identified in chlamydia-infected cell cytosolic fraction can degrade
both USF-1 and RFX5. This proteasome-like activity is dependent on chlamydial but not host
protein synthesis. Host preexisting proteasomes may not be required for the unique protea-
some-like activity. These observations suggest that chlamydia-secreted factors may directly par-
ticipate in the proteasome-like activity. Efforts to identify the chlamydial factors are underway.
These findings provide novel information on the molecular mechanisms of chlamydial evasion
of host immune recognition.
Key words: MHC class I suppression • RFX5 degradation • IFN-
 
g
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Introduction
 
CD8
 
1
 
 T cell–mediated immunity plays an important role
in controlling intracellular pathogen infections (1, 2), and
MHC class I expression on infected cells is a prerequire-
ment for CD8
 
1
 
 T cell recognition of the infected cells (3).
The CD8
 
1
 
 T cell recognition of the infected cells may lead
to both cell killing (4) that may enable the infected hosts to
eliminate the intracellularly sequestrated pathogens and se-
cretion of cytokines (5) that may be able to restrict the in-
tracellular pathogen growth. Therefore, to avoid CD8
 
1
 
 T
cell recognition, many intracellular pathogens such as cy-
 
tomegalovirus (6), 
 
Toxoplasma gondii 
 
(7), 
 
Listeria monocytoge-
nes
 
 (8), and 
 
Leishmania donovani 
 
(9) have evolved strategies
for inhibiting MHC class I expression on the infected cells.
The natural target cells of intracellular pathogens such as
epithelial cells can express MHC class I molecules constitu-
tively, and the expression level of MHC class I molecules
on these cells can be significantly upregulated with IFN-
 
g
 
stimulation (10). The IFN-
 
g
 
 induction of MHC class I ex-
pression may greatly enhance the ability of the infected
cells to present the intracellular pathogen-derived peptide
on cell surface for CD8
 
1
 
 T cell recognition (11). At tran-
scription level, both constitutive and IFN-
 
g
 
–inducible
MHC class I expression require a common downstream
transcription complex, RFX. The RFX complex, consist-
ing of multiple subunits including RFX5, RFXAP, and
p41 (12), can directly bind to a conserved X1 regulatory el-
 
ement upstream of MHC class I heavy chain and 
 
b
 
2-micro-
 
globulin (
 
b
 
2M)
 
1
 
 genes (13, 14). Mutations in RFX5 gene
abolish binding of RFX to the X1 regulatory element (15),
and human cells carrying RFX5 mutations can not prop-
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2M, 
 
b
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EndoH, endoglycosidase H; MOI, multiplicity of infection; MOMP, ma-
jor outer membrane protein; RT, reverse transcriptase; STAT, signal
transducer and activator of transcription; TPP2, tripeptidyl peptidase II;
USF, upstream stimulation factor. 
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erly express MHC class I even in the presence of IFN-
 
g
 
stimulation (16), demonstrating the importance of RFX5
in both constitutive and IFN-
 
g
 
–inducible MHC class I ex-
pression. Therefore, the RFX transcription complex can be
a vulnerable (or effective) target for microbial pathogens to
suppress both constitutive and IFN-
 
g
 
–inducible MHC
class I expression. However, although many viruses have
been found to evolve strategies for interrupting MHC class
I expression by acting at the posttranslation level (17–20),
so far there is no report on microbial interruption of MHC
expression by targeting at the transcription complex RFX.
Chlamydia is an obligate intracellular pathogen of hu-
mans and animals and has adapted so successfully that it can
persist in hosts for a long period of time after an acute in-
fection (21, 22). Chlamydial immune evasion may contrib-
ute to the chlamydial persistence. We have previously
demonstrated that chlamydia can suppress IFN-
 
g
 
–inducible
MHC class II expression by degrading upstream stimulation
factor (USF)-1 (23), which may allow the infected cells to
avoid CD4
 
1
 
 T cell recognition. To escape from CD8
 
1
 
 T
cell–mediated immunity, chlamydia has been found to pos-
sess a strong antiapoptotic activity for potentially evading
the killing mechanisms of CD8
 
1
 
 T cells (24). However,
even without effective killing of the target cells, CD8
 
1
 
 T
cell recognition of the infected cells may still lead to secre-
tion of lymphokines that are able to restrict intracellular
pathogen growth. This selection pressure may further drive
intracellular pathogens to evolve strategies for preventing
CD8
 
1
 
 T cell recognition by altering MHC class I antigen
presentation (25–28). Since the intracellular chlamydia or-
ganisms can persist in a wide range of host species for a long
period of time, chlamydia may have also evolved strategies
for evading CD8
 
1
 
 T cell recognition. To test this hypothe-
sis, we evaluated the effect of chlamydial infection on
MHC class I expression with or without IFN-
 
g
 
 stimula-
tion. We found that chlamydia can inhibit both constitu-
tive and IFN-
 
g
 
–inducible MHC class I expression by de-
grading a critical transcription factor, RFX5, that is
essential for MHC class I expression. Furthermore, a
chlamydia-dependent proteasome-like activity (CPA) was
identified in the chlamydia-infected cell cytosolic fraction.
CPA was found to be responsible for both USF-1 and
RFX5 degradation. We hypothesize that a chlamydial fac-
tor(s) may directly participate in CPA, as the CPA required
chlamydial but not host protein synthesis and was likely to
be independent of preexisting host proteasomes.
 
Materials and Methods
 
Chlamydial Infection and IFN-
 
g
 
 Stimulation.
 
The following hu-
man cell lines were used: HeLa (cervical epithelium; American
Type Culture Collection [ATCC]); HL (airway epithelium;
Washington Research Foundation; reference 29); MRC-5 (fibro-
blast; ATCC), and WSI (fibroblast; provided by Dr. P.J. van den
Elsen, Leiden University Medical Center, Leiden, The Nether-
lands). Cells were infected with 
 
Chlamydia trachomatis
 
 LGV2 strain
at a multiplicity of infection (MOI) of 5 or as indicated and for
24–30 h or as indicated in individual experiments (23). Cells with
 
or without infection were stimulated with human IFN-
 
g
 
(PharMingen) at 200 U/ml or as indicated for another 10 h (for
reverse transcriptase [RT]-PCR analysis) or 24–30 h (for flow cy-
tometry and Western blot analysis).
 
Flow Cytometry.
 
Cell samples were stained with mouse anti–
HLA-A, -B, and -C (HB94; ATCC), mouse anti–human 
 
b
 
2M
(32271A; PharMingen), or normal mouse IgG (Zymed Labs.,
Inc.). Primary antibody binding was detected using goat anti–
mouse IgG 
 
1
 
 IgM conjugated with FITC (Caltag Labs.) and
analyzed with a FACSCalibur™ equipped with CELLQuest™
software (Becton Dickinson). Dead cells were excluded by pro-
pidium iodide staining.
 
Western Blot Assay.
 
Western blot assay was carried out as we
previously described (23, 24). Rabbit antibodies were used to de-
tect RFX5 (Rockland Immunochemicals), USF-1 (SC-229;
Santa Cruz Biotechnology, Inc.), USF-2 (SC-862; Santa Cruz),
and 11S regulatory subunit PA28
 
a
 
 (PW8185; AFFINITI Re-
search Products Ltd.). Mouse antibodies were used to detect
HLA-A and -B (HB296; ATCC), 
 
b
 
2M (HB149; ATCC), 
 
b
 
1 in-
tegrin (provided by Dr. J. Wilkins, University of Manitoba, Man-
itoba, Canada), 20S proteasome 
 
a
 
 subunit HC2 (MCP20; AF-
FINITI), 20S proteasome 
 
a
 
 subunit HC3 (MCP21; AFFINITI),
20S proteasome subunits 
 
a
 
1, 2, 3, 5, 6, and 7 (MCP231; AF-
FINITI), 20S proteasome subunit 
 
b
 
7 (MCP205; AFFINITI), and
a chlamydial major outer membrane protein (MOMP; clone
MC22; our unpublished data). Primary antibody binding was de-
tected with horseradish peroxidase–conjugated goat anti–mouse
IgG or –rabbit IgG, depending on the source of the primary anti-
bodies, and visualized using an ECL kit (Amersham).
 
RT-PCR Assay.
 
Cell samples were collected for RNA ex-
traction using the Rneasy™ Mini Kit from QIAGEN Inc. 2 
 
m
 
g
of total RNA was used for each cDNA synthesis with random
primers and the 1st Strand cDNA synthesis kit from Boehringer
Mannheim. Aliquots of the cDNA samples were used as template
for amplifying specific gene fragments by PCR reactions (23).
The primers used for gene amplification were: for 
 
b
 
2M amplifi-
cation, 5
 
9
 
-TCTCGCTCCGTGGCCTTAG (forward) and 5
 
9
 
-
ATGTCTCGATCCCACTTAACT (reverse); for HLA class I
heavy chain amplification, 5
 
9
 
-GTGGGCTAGGTGGACGAC
(forward) and 5
 
9
 
-TTCTCCAGGTATCTGCGG (reverse); for
USF-1 amplification, 5
 
9
 
-TGGCACTGGTCAATTCTTTGTG
(forward) and 5
 
9
 
-GTTGCTGTCATTCTTGATGAC (reverse);
for RFX5, 5
 
9
 
-TCCTTCAGTTCCATCGTTGAG (forward)
and 5
 
9
 
-TTCAGCTGTCCTCTTGACACC (reverse); and for
 
b
 
-actin, 5
 
9
 
-GTGGGGCGCCCCAGGCACCA (forward) and
5
 
9
 
-CTCCTTAATGTCACGCACGATTTC (reverse). 
 
b
 
-actin
mRNA detection was used as an internal control for the amount
of cDNA synthesized. To ensure the specificity of the mRNA
detection, all primers were designed to cover at least two exons,
and parallel samples without RT were run as negative controls.
The amplified DNA products were run on an agarose gel and vi-
sualized with ethidium bromide staining.
 
Immunoprecipitation.
 
Immunoprecipitation was carried out as
described elsewhere (30) with some modifications. For antibody
depletion experiments, cell samples were dounced to make the
cytosolic fraction S100 as we previously described (24), and the
proteasome complexes in S100 were precipitated with the mAb
MCP21 (specific to 20S proteasome 
 
a
 
 subunit HC3; reference
31) previously bound to protein G–Sepharose beads. The S100
supernatants after depletion of the proteasome complexes were
compared with the S100 without prior antibody depletion for
their ability to degrade RFX5 in a cell-free assay (see below). For
two-dimensional PAGE analysis, cells with or without chlamy- 
1527
 
Zhong et al.
 
dial infection were continuously labeled with S
 
35
 
–methionine/
cysteine (ICN) for 24 h, and the radiolabeled cells were lysed
with a RIP buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS,
1 mM PMSF, 1 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leupeptin, and 1 
 
m
 
g/
ml pepstatin A (24). The lysates were precipitated with the
MCP21 antibody, and the precipitated pellets were run on two-
dimensional PAGE. The first dimension was nonequilibrium pH
gradient electrophoresis toward the cathode for 3 h at 400 V. The
second dimension run was in Laemmli SDS-PAGE gels with 12%
polyacrylamide. The gels were then fixed and subjected to auto-
radiography. For pulse–chase labeling experiments, cells with or
without chlamydial infection were pulsed with S
 
35
 
–methionine/
cysteine for 30 min, and the pulsed cells were washed, detached,
and aliquoted into four portions. One portion was immediately
lysed in RIP buffer as the zero chase time point sample. The
other three portions were chased in normal growth medium at
37
 
8
 
C for an additional 30 min, 2 or 6 h before they were lysed.
The cell lysates were precipitated with an anti–HLA-A, -B, and
-C (HB94; ATCC) and anti-
 
b
 
2M (HB149; ATCC) antibody,
respectively. Portions of the anti–HLA-A, -B, and -C antibody–
precipitated pellets were treated with endoglycosidase H (EndoH;
catalog no. 100119; Boehringer Mannheim) in 60 mM sodium
acetate, pH 5.4, as previously described (30). The precipitated
pellets with or without the EndoH treatment were run on SDS-
PAGE gels for autoradiography analysis.
 
Cell-free Proteolysis Assays.
 
The S100 fractions made from
chlamydia-infected cells were used as the source of enzyme and
were incubated with cellular extracts containing target proteins
for 1 h at 37
 
8
 
C. The incubated mixtures were then analyzed for
specific target protein degradation on Western blot. For inhibi-
tion experiments, inhibitors were added to the enzyme prepara-
tions before mixing with the target proteins. Inhibitors used in
this study include: lactacystin (catalog no. 426102; Calbiochem
Corp.), MG115 (carbobenzoxy-
 
l
 
-leucyl-
 
l
 
-leucyl-
 
l
 
-norvalinal;
catalog no. 474780; Calbiochem), MG-132 (carbobenzoxy-
 
l
 
-leucyl-
 
l
 
-leucyl-
 
l
 
-leucinal; catalog no. 474790; Calbiochem),
PSI (Z-Ile-Glu(OBu)-Ala-Leu-H [aldehyde]; Peptide Institute
Inc.), AAF (Ala-Ala-Phe chloromethylketone; Sigma Chemical
Co.), PMSF (Sigma), pepstatin A (Sigma), and aprotinin (Sigma).
 
Column Chromatography.
 
The S100 fractions from chlamydia-
infected cells were applied to a Mono Q-anion exchange or a Su-
perdex 200 size exclusion column (Pharmacia Biotech Inc.). A
linear gradient from 0 to 1 M NaCl of eluent B was used for an-
ion exchange, and a phosphate buffer, pH 7.4, was used for size
exclusion chromatography with an AKTA purifier 10 instrument
(Pharmacia Biotech Inc.). Fractions were assayed for degradation
of the nuclear transcription factor RFX5 and for the presence of
host cell proteasome subunits.
 
Results
 
Both Constitutive and IFN-
 
g
 
–inducible MHC Class I Ex-
pressions Are Inhibited in Chlamydia-infected Cells.
 
To test
our hypothesis that chlamydia may suppress MHC class I
expression, we evaluated both constitutive and IFN-
 
g
 
–induc-
ible MHC class I expression in chlamydia-infected cells. A
flow cytometry approach was first used to compare the sur-
face expression of MHC class I in normal HeLa and
chlamydia-infected HeLa cells with or without IFN-
 
g
 
stimulation (Fig. 1 A). Normal HeLa cells expressed a basal
level of MHC class I heavy chain (HLA-A, -B, and -C) and
 
b
 
2M, and the expression of these molecules was signifi-
cantly upregulated by IFN-
 
g
 
 stimulation. However, HeLa
cells infected with chlamydia displayed remarkably reduced
levels of both HLA-A, B, and -C and 
 
b
 
2M regardless of
IFN-
 
g
 
 stimulation. These observations suggest that
chlamydial infection completely blocked the IFN-
 
g
 
 induc-
tion of MHC class I molecules and also reduced the consti-
tutive expression level.
The chlamydial suppression of MHC class I expression
was further evaluated in multiple cell lines on Western blot
(Fig. 1, B and C). All four human cell lines tested (two ep-
ithelial cells, HeLa and HL, and two fibroblast cells,
MRC-5 and WSI) displayed a basal level of MHC class I
heavy chain (HLA-A and -B; Fig. 1 C) and 
 
b
 
2M molecule
(Fig. 1 B). The basal level was significantly reduced after
chlamydial infection, suggesting that chlamydial infection
can suppress the constitutive expression of MHC class I
molecules. Although IFN-
 
g
 
 stimulation greatly upregulated
the MHC class I heavy chain and 
 
b
 
2M expression in all
four cell lines, chlamydial infection completely inhibited
the IFN-
 
g
 
 induction. These results confirm that chlamydial
infection can inhibit both constitutive and IFN-
 
g
 
–induc-
ible expression of MHC class I molecules. The fact that to-
tal cellular level of MHC class I was detected in the West-
ern blot assay suggests that the chlamydia-suppressed cell
surface expression of MHC class I molecules shown in Fig.
1 A may not be due to an alternation of MHC class I intra-
cellular trafficking. To further determine whether chlamy-
dial infection affects intracellular trafficking of MHC class I
molecules, we compared the maturation process of both
MHC class I heavy chains and 
 
b
 
2M molecule in mock-
and chlamydia-infected cells (Fig. 1 D). Although the over-
all levels of class I heavy chains and 
 
b
 
2M molecules in the
chlamydia-infected cells was lower than that in mock-
infected cells, the maturation rate (comparing samples
chased up to 2 h) and half-life (comparing 6 h–chased sam-
ples) of class I heavy chains and 
 
b
 
2M molecule were similar
between the mock- and chlamydia-infected cells. The
MHC class I heavy chains gained partial and full resistance
to EndoH digestion at 30 min and 2 h after pulse, respec-
tively, in both mock- and chlamydia-infected cells (data
not shown). This observation is consistent with a previous
finding that chlamydial infection did not affect the traffick-
ing of host cell glycoproteins including MHC class I heavy
chains (32). As chlamydial infection did not alter MHC
class I heavy chain and 
 
b
 
2M intracellular trafficking but
significantly reduced the total protein level, we hypothesize
that chlamydia may inhibit MHC class I expression at ei-
ther the transcription or translation level.
We evaluated the mRNA levels of both the MHC class
I heavy chain and 
 
b
 
2M in cells with or without chlamy-
dial infection and with or without IFN-
 
g
 
 stimulation us-
ing a semiquantitative RT-PCR assay (Fig. 1 E). Chlamy-
dial infection significantly inhibited both MHC class I
heavy chain and 
 
b
 
2M mRNA expression, especially that
induced by IFN-
 
g
 
, which suggests that the chlamydial
suppression of MHC class I occurred at the transcription
level. We next evaluated the effects of chlamydial infec- 
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tion on transcription factors required for MHC class I ex-
pression.
 
Chlamydial Inhibition of MHC Class I Expression Correlates
with Loss of Host Transcription Factor RFX5 in Chlamydia-
infected Cells.
 
It has been demonstrated that RFX5 is an
essential component of transcription complex RFX required
for both constitutive and IFN-
 
g
 
–inducible MHC class I
expression (16). We measured the level of RFX5 protein
in chlamydia-infected cells (Fig. 2 A). HeLa cells displayed
normal levels of RFX5, HLA-A and -B heavy chains,
b2M, and b1 integrin molecules, and the expression of
HLA-A and -B heavy chains and b2M was further upregu-
lated upon IFN-g stimulation. However, HeLa cells in-
fected with chlamydia regardless of IFN-g stimulation
showed a significant reduction in HLA-A and -B and b2M
and complete loss of RFX5. The level of b1 integrin (as a
control membrane protein) in chlamydia-infected cells was
largely unchanged. The chlamydial MOMP was only de-
tected in chlamydia-infected cells. These observations
demonstrated a correlation between the inhibition of
MHC class I expression and the loss of the transcription
factor RFX5 in chlamydia-infected cells.
We next tried to understand how RFX5 was completely
lost in chlamydia-infected cells. RFX5 mRNA levels in
normal and chlamydia-infected HeLa cells were compared
using RT-PCR, and no difference was found (data not
shown), suggesting that RFX5 mRNA was normally tran-
scripted in chlamydia-infected cells and that the loss of
RFX5 protein may occur at or downstream of translation
level. We have previously identified a CPA in chlamydia-
infected cells. This CPA selectively degraded transcription
factor USF-1, and the CPA-mediated degradation was sen-
sitive to lactacystin inhibition (23). We tested whether the
lactacystin-sensitive CPA could also degrade RFX5 (Fig. 2
B). In this experiment, a nuclear protein extract was used as
the source of RFX5. To exclude the possibility of direct
degradation of MHC class I molecules, the MHC class I
molecules were also used as degradation targets in the same
assay. Since we have determined that a cytosolic soluble
protein fraction after 100,000 g centrifugation (designated
as S100) contains the highest CPA (data not shown), the
S100 from chlamydia-infected HeLa cells (chlamydia S100)
was used as the source of the CPA, and the S100 from nor-
mal HeLa cells (HeLa S100) was used as control. Neither
chlamydia S100 nor HeLa S100 alone showed any signifi-
cant amounts of target proteins HLA-A and -B, b2M (both
membrane proteins), or RFX5 (nuclear protein), suggest-
ing that the S100 fractions used in this experiment had
minimal contamination with proteins from other cellular
compartments. When HeLa S100 was incubated with the
target proteins, all target proteins detected were still intact
(Fig. 2 B). However, incubation with chlamydia S100
completely degraded RFX5 but not HLA-A and -B and
b2M. Furthermore, RFX5 degradation was inhibited by
lactacystin. These observations demonstrated that the lacta-
cystin-sensitive CPA in chlamydia S100 selectively de-
graded the transcription factor RFX5, which further
strengthens a causal relationship between chlamydia-
Figure 1. Chlamydia inhibits
both constitutive and IFN-g–
inducible MHC class I expres-
sion in infected cells. HeLa cells
with or without chlamydial in-
fection were stimulated with
IFN-g or unstimulated and col-
lected for flow cytometry (A),
Western blot (B and C), and
RT-PCR (E) analysis. Chlamy-
dia prevents both constitutive
and IFN-g–inducible HLA-A,
-B, and -C heavy chain and b2M surface expression (A). Chlamydia sup-
presses the total cellular protein level of both constitutive and IFN-g–
inducible b2M (B) and HLA-A and -B heavy chains (C) in various hu-
man cell lines. Chlamydia inhibits the mRNA expression of both MHC
class I heavy chains and b2M (E). For pulse–chase labeling experiment
(D), HL cells with or without chlamydial infection were metabolically la-
beled with S35–methionine/cysteine for 30 min, and the pulsed cell sam-
ples were aliquoted and chased for various times as indicated. Mature or
immature bands correspond to proteins resistant or sensitive to EndoH di-
gestion as determined in a separate experiment (data not shown).1529 Zhong et al.
induced degradation of RFX5 and chlamydial suppression
of MHC class I expression. Combining this data with our
previous observation on chlamydial suppression of IFN-g–
inducible MHC class II expression (23), we conclude that
the same CPA was responsible for the degradation of both
RFX5 and USF-1. The next step was to further character-
ize the CPA.
Degradation of RFX5 Is Dissociated from Host Cell Protea-
somes. Various inhibitors known to be able to inhibit dif-
ferent eukaryotic proteases and proteasomes were used for
characterizing the CPA by measuring RFX5 degradation in
a cell-free assay (Fig. 3 A). Chlamydia S100 completely de-
graded RFX5, whereas HeLa S100 failed to do so. The
RFX5 degradation was inhibited by the proteasome inhib-
itor lactacystin at a final concentration of 20 mM. These
observations confirmed that the typical CPA was responsi-
ble for the RFX5 degradation in this assay. Interestingly,
the CPA-mediated RFX5 degradation was not inhibitable
by other proteasome inhibitors, including PSI, MG115,
and MG132 (carbobenzoxy-l-leucyl-l-leucyl-l-leucinal),
suggesting that the CPA is different from the conventional
20S or 26S proteasome activity. It was recently demon-
strated that a tripeptidyl peptidase II (TPP2) and some
other AAF-inhibitable proteases can substitute the function
of the conventional proteasomes in stressed cells (33, 34).
We evaluated the role of TPP2 in RFX5 degradation. The
potent TPP2 inhibitor AAF, even at a final concentration
of 100 mM, failed to block the RFX5 degradation, suggest-
ing that AAF-inhibitable protease activities including TPP2
were not involved in the CPA. We also evaluated the ef-
fects of many other protease inhibitors such as phenylmeth-
ylsulfonyl fluoride, pepstatin A, and aprotinin on the CPA,
and no inhibition was found with any of these inhibitors
(data not shown). Together, these observations suggest that
the CPA represents a distinct proteasome-like activity.
We next compared the 20S proteasome precipitation
patterns between normal HeLa and chlamydia-infected
HeLa cells (Fig. 3 B). The two-dimensional gel distribution
pattern of the radioisotope-labeled 20S proteasome sub-
units precipitated from the chlamydia-infected HeLa cells
was similar to that from normal HeLa cells, suggesting that
chlamydial infection did not significantly alter the 20S pro-
teasome subunit composition. It is, therefore, unlikely that
the CPA is caused by chlamydia-induced modification of
host proteasomes.
A column chromatography approach was used to further
differentiate the CPA (measured using the RFX5 degrada-
tion assay) from the normal host cell proteasomes (Fig. 3, C
and D). The chlamydia S100 was subjected to an ion ex-
change (Fig. 3 C) or size exclusion (Fig. 3 D) column sepa-
ration, and the separated fractions were measured for both
the CPA and the presence of host proteasome components.
Maximal CPA was found in fraction 12 of the ion ex-
change column, while most of the detected proteasome
subunits (31, 35) existed in fraction 14. Similarly, there was
no obvious overlapping between the CPA and any of the
detected 20S proteasome subunits in fractions from the size
exclusion column (Fig. 3 D). These observations suggest
that host proteasomes may not be required for the CPA.
However, there are still some overlaps between the host
proteasomes and the CPA in both column separation as-
says, although at a minimal level, which may suggest a role
of the overlapping minority of the host proteasomes in the
CPA. The potential contribution of host proteasomes to
the CPA was further evaluated using the following anti-
body depletion experiment (Fig. 3 E). Either HeLa S100 or
chlamydia S100 was subjected to precipitation with the
mAb MCP21, and the supernatants after precipitation (des-
ignated as S100-de) were compared with intact S100 for
their ability to degrade RFX5 (Fig. 3 E, top panel).
Chlamydia S100 completely degraded RFX5 (Fig. 3 E),
and, more importantly, the chlamydia S100-de still caused
efficient degradation of RFX5 (Fig. 3 E), suggesting that
the 20S host proteasomes were not required for the CPA,
as depletion of the 20S proteasome did not affect RFX5
degradation. The removal of host 20S proteasomes was suf-
ficient, as the proteasome subunits were no longer detect-
able in S100 with prior antibody depletion (Fig. 3 E, bot-
tom panel).
Both the Inhibition of MHC Class I Molecule Expression and
the Degradation of RFX5 Are Dependent on Chlamydial but Not
Host Protein Synthesis. We have demonstrated that the
degradation of RFX5 was dissociated from preexisting host
proteasomes, which suggests that the CPA responsible for
Figure 2. Inhibition of MHC class I expression corre-
lates with RFX5 degradation. (A) HeLa cells with or with-
out chlamydial infection and with or without IFN-g stim-
ulation were analyzed on Western blot for the levels of
RFX5, HLA-A and -B heavy chains, b2M, b1 integrin (as
a control membrane protein), and a chlamydial MOMP.
Chlamydia-infected cell samples showed reduced levels of
HLA heavy chain and b2M and complete loss of RFX5.
(B) Cell-free assay analysis of HLA-A and -B heavy chain,
b2M, and RFX5 degradation. Cytosolic S100 fractions
from either normal HeLa (HeLa S100) or chlamydia-
infected HeLa cells (chlamydia S100) were incubated with
the corresponding target proteins (either a membrane pro-
tein extract as the source of HLA-A and -B heavy chains
and b2M or a nuclear protein extract as the source of
RFX5). The incubated mixtures were analyzed on Western blot for the levels of the residual target proteins with the corresponding antibodies. Chlamy-
dia S100 selectively degrades RFX5 but not HLA-A and -B heavy chains and b2M.1530 Chlamydial Inhibition of MHC Class I
RFX5 degradation may be produced by newly synthesized
proteins. To test whether chlamydial protein synthesis is re-
quired for the CPA, we first correlated the degradation of
RFX5 with chlamydial infection dose (Fig. 4 A) and infec-
tion time course (Fig. 4 B). As MOI (ratio of number of or-
ganisms/number of host cells) increased, more chlamydial
MOMP protein was produced and more RFX5 was de-
graded, suggesting a correlation between the amount of
chlamydial protein synthesis and severity of the RFX5 deg-
radation. The time course study also revealed a similar cor-
relation: as infection prolonged, more chlamydial MOMP
protein was synthesized and more RFX5 was degraded (Fig.
4 B). USF-1 and -2 levels were also monitored in the dose
titration and time course experiments using an antibody that
can bind to both USF isoforms. USF-1 was used as positive
control, since we have previously demonstrated the degra-
dation of USF-1 in chlamydia-infected cells (23). USF-2
was used as negative control, as we found that the level of
USF-2 was not affected by chlamydial infection (23). Con-
sistent with our previous observation (23), USF-1 degrada-
tion correlated with the infection severity, whereas USF-2
was maintained at a similar level in both the time course and
Figure 3. Degradation of RFX-5 is dissociated from host proteasomes. (A) Inhibition of RFX5 degradation by proteasome inhibitors in a cell-free as-
say. Chlamydia S100 or HeLa S100 cells were incubated with a nuclear protein extract (as a source of RFX5) in the presence or absence of various inhib-
itors (proteasome inhibitors: lactacystin, PSI, MG115, and MG132; TPP2 inhibitor: AAF). The incubated mixtures were then analyzed on Western blot
for residual RFX5 levels. ns denotes nonspecific binding. (B) Comparison of 20S proteasome subunit distribution patterns between normal and chlamy-
dia-infected HeLa cell samples. HeLa cells with or without chlamydial infection were metabolically labeled with S35–methionine/cysteine for 24 h, and
the cell lysates were precipitated with antibody MCP21 (recognizing one of the 20S proteasome subunits). The precipitates were subjected to a two-
dimensional PAGE, and the protein patterns were visualized by autoradiography. The 20S proteasome subunits were numbered based on the description
in reference 31. (C) Ion exchange column separation of RFX5 cleavage activity from host proteasome subunits. Chlamydia S100 was applied to a Mono
Q-anion exchange column, which was eluted with a linear gradient of 0–1 M NaCl, and the eluent protein concentration was monitored using 280 nm
absorbence. The eluted fractions with even numbers were measured for RFX5 cleavage in a cell-free assay and detected for the presence of host proteins,
including various a subunits, b7 subunit of the 20S proteasome, and 11S regulatory PA28a on Western blot. (D) Size exclusion column separation of
RFX5 cleavage activity from host proteasome subunits. Chlamydia S100 was applied to a Superdex 200 size exclusion column, which was eluted with
PBS. The eluted fractions were measured as described in the legend for panel C. (E) Effect of 20S proteasome depletion on RFX5 cleavage activity.
HeLa or chlamydia S100 was precipitated with antibody MCP21 to deplete the 20S proteasome complexes. The supernatants after depletion were com-
pared for RFX5 cleavage activity with the intact S100 (S100 without prior antibody depletion). The RFX5 cleavage activity was measured in a cell-free
assay, and the residual RFX5 was detected on Western blot (top panel). The efficiency of the 20S proteasome depletion was evaluated by monitoring re-
sidual 20S proteasome subunits in the S100 with prior antibody depletion on Western blot (bottom panel). Although both heavy and light chains of the
antibody MCP21 were detected, the proteasome subunit HC3 was no longer detectable in the depleted supernatant.1531 Zhong et al.
dose titration experiments. The correlation between the
chlamydial infection severity and both RFX5 and USF-1
degradation suggests that chlamydial protein synthesis may
be required for the CPA. We used antibiotics specifically in-
hibiting either prokaryotic or eukaryotic protein synthesis
to further confirm whether chlamydial or host protein syn-
thesis is required for the CPA (Fig. 4 C). Normal host cells
expressed a basal level of MHC class I heavy chains, b2M
(both upregulated by IFN-g), RFX5, and USF-1, whereas
chlamydia-infected cells displayed a remarkably reduced
level or even complete loss of these molecules regardless of
IFN-g stimulation (Fig. 4 C). The chlamydial MOMP was
detected only in chlamydia-infected cell samples. Treatment
with rifampin (inhibiting prokaryotic transcription) or
chloramphenicol (inhibiting prokaryotic translation) com-
pletely inhibited chlamydial MOMP protein synthesis, pre-
vented degradation of the transcription factors RFX5 and
USF-1, and restored MHC class I expression (Fig. 4 C),
suggesting that chlamydial protein synthesis is necessary for
both the inhibition of MHC class I and degradation of
RFX5 and USF-1. Treatment with penicillin (only inhibit-
ing chlamydial particle assembly without affecting chlamy-
dial protein synthesis) was unable to block chlamydial
MOMP protein synthesis and failed to prevent degradation
of RFX5 and USF-1 and inhibition of MHC class I expres-
sion, suggesting that chlamydial particle assembly is not re-
quired for the chlamydial effects. Finally, cycloheximide
treatment (inhibiting eukaryotic protein synthesis) did not
affect chlamydial protein synthesis and various chlamydia-
induced effects, suggesting that host newly synthesized pro-
teins are not required for the suppression of MHC class I
and degradation of RFX5 in chlamydia-infected cells.
Discussion
Animal hosts have evolved multiple, sometimes seem-
ingly wasteful, defense responses for controlling microbial
infections, which, in turn, select for microbial pathogens
with the ability to evade multiple host defense mechanisms.
We have found that, like many other successful intracellular
pathogens, chlamydia has evolved varied strategies for coun-
teracting both immune recognition and immune effector
mechanisms (23, 24). The chlamydial immune evasion may
contribute to the success of chlamydial persistence, a major
cause of chlamydia-induced diseases in humans (36). To
avoid CD41 T cell recognition, chlamydia can efficiently
inhibit IFN-g–inducible MHC class II expression by de-
grading transcription factor USF-1 (23). USF-1 degradation
may also affect MHC class I expression, as USF-1 is re-
quired for the expression of class II transactivator (CIITA)
and CIITA may participate in the transcription of IFN-g–
inducible MHC class I genes (37). However, our current
finding on chlamydial suppression of both constitutive and
IFN-g–inducible MHC class I expression cannot be ex-
plained by the USF-1 degradation alone. This is because (a)
many USF-1/CIITA-independent pathways can also medi-
ate IFN-g induction of MHC class I expression (reference
10) and (b) neither CIITA nor USF-1 has been found to
play any significant role in the constitutive expression of
MHC class I molecules. Many epithelial cells lacking CIITA
can constitutively express MHC class I molecules. There-
fore, the chlamydial suppression of both constitutive and
IFN-g–inducible MHC class I expression is likely to de-
pend on a mechanism independent of USF-1 degradation.
We have correlated the chlamydial inhibition of MHC
class I expression with the degradation of RFX5, a critical
downstream transcription factor essential for both constitu-
tive and IFN-g–inducible MHC class I expression (16).
Figure 4. Chlamydial but not host protein synthesis is required for
both the degradation of RFX5 and suppression of HLA-A and -B heavy
chains and b2M. (A) Correlation between infection dose and RFX5 deg-
radation. 30 h after chlamydial infection at various MOI, HeLa cells were
analyzed for the levels of chlamydial MOMP and host RFX5, USF-1,
and USF-2 proteins on Western blot. The anti–USF-2 antibody used in
this experiment can bind to both USF-1 and -2. These two USF isoforms
can be separated on blots if gels are run far enough. Since we have previ-
ously shown that USF-1 is degraded in chlamydia-infected cells (23),
USF-1 is used as a positive control. Since USF-2 protein level is usually
not altered by chlamydial infection, it serves as a negative control. ns de-
notes nonspecific binding. (B) Time course relationship between chlamy-
dial growth and RFX5 degradation. At various time points after infection,
HeLa cell samples were analyzed on Western blot as described in A. (C)
Inhibition of chlamydial but not host protein synthesis prevents RFX5
degradation and restores HLA-A and -B heavy chain and b2M expres-
sion. Rifampin (RF; final concentration 5 0.1 mg/ml), chloramphenicol
(CH; 60 mg/ml) and penicillin (PG; 100 mg/ml) were added at the be-
ginning of chlamydial infection and maintained throughout the culture.
Cycloheximide (CY; 10 mg/ml) was added to the culture 10 h before
IFN-g treatment and maintained during the IFN-g stimulation. The
treated HeLa cells were analyzed for protein levels of HLA-A and -B
heavy chains, b2M, RFX5, USF-1, and chlamydial MOMP on Western
blot. ns denotes nonspecific binding.1532 Chlamydial Inhibition of MHC Class I
RFX5 is a key component of the transcription complex
RFX (16, 38). Human cells carrying RFX5 mutations can-
not properly express MHC class I even in the presence of
IFN-g stimulation, and transfection of these mutant cells
with plasmid encoding competent RFX5 can restore the
normal expression of MHC class I molecules (16). There-
fore, RFX5 degradation may represent an effective strategy
for suppressing MHC class I expression by the chlamydia
organisms. Interestingly, MHC class II molecule expression
also requires the RFX complex (13, 14). In fact, RFX
complex is a shared downstream transcription complex es-
sential for both MHC class I and class II gene transcription
(14). Humans carrying RFX5 mutations develop type C
bare lymphocyte syndrome because of deficiency in MHC
class II expression (15). Therefore, besides the degradation
of USF-1 (23), the chlamydia-induced RFX5 degradation
also contributes to the suppression of MHC class II expres-
sion in chlamydia-infected cells. Degradation of both
RFX5 and USF-1 may allow chlamydia to ensure that both
MHC class I and class II expression are efficiently sup-
pressed in the infected cells.
Blocking the function of transcription factors required for
mounting host defense responses may represent an effective
immune evasion strategy used by intracellular pathogens. It
has been recently shown that adenoviral E1A can directly
bind to signal transducer and activator of transcription 1
(Stat1) and block Stat1-dependent gene activation (39). It
has also been demonstrated that human cytomegalovirus
can induce degradation of Janus tyrosine kinase (JAK)1 and
block IFN-g JAK/STAT signaling pathways (40). Here, we
report that chlamydia, an obligate intracellular pathogen,
has evolved the strategy for directly degrading host tran-
scription factors USF-1 (23) and RFX5.
What is the functional outcome of the chlamydia-
induced suppression of MHC class I expression? This study
has demonstrated that chlamydial infection caused RFX5
degradation 17 h after infection (Fig. 4 B) and induced a
significant suppression of cell surface MHC class I mole-
cules 24 h or later after infection (Fig. 1 A). Therefore, at an
early stage during chlamydial infection, chlamydial early
proteins (41) and even structural proteins (42) can be pro-
cessed and presented by host MHC molecules, which may
allow antigen-specific T cells to recognize and attack the
infected cells. This scenario may provide an explanation for
some in vitro observations that CD81 T cells were able to
lyse chlamydia-infected target cells (43, 44). However, once
the chlamydial antiapoptotic activity (24) and chlamydia-
induced suppression of MHC class I molecules are devel-
oped, the chlamydia-specific T cells may not be able to
detect and attack the infected cells anymore, which is consis-
tent with the observations that chlamydia-immunized CTLs
failed to lyse chlamydia-infected cells in some cases (45, 46).
More importantly, the chlamydial suppression of MHC class
I may play a significant role in facilitating chlamydial sur-
vival during natural infection. It has been shown that
chlamydia-infected cells can only release a significant
amount of inflammatory cytokines 24 h after infection (47),
suggesting that the circulating chlamydia-specific T cells are
most effectively recruited to the infection sites only after the
middle cycle of chlamydial growth (24 h after infection).
Therefore, the chlamydial suppression of MHC class I ex-
pression, occurring at a time when host T cell attack on the
chlamydia-infected cells is most likely to happen, may be
beneficial for chlamydial survival in the infected hosts. This
hypothesis is further supported by various previous findings
that mice deficient in b2M (48) or perforin (49) did not
show enhanced susceptibility to chlamydial infection.
We have demonstrated that a CPA identified in chlamy-
dia-infected cell cytosolic fraction is responsible for the
degradation of both USF-1 and RFX5. The CPA is depen-
dent on chlamydial but not host protein synthesis. Al-
though we have presented considerable evidence showing
that preexisting host 20S proteasomes may not be required
for the CPA, we cannot completely exclude the involve-
ment of host proteasomes in CPA. This is because there is a
possibility that only small amounts of proteasome subunits,
after the chlamydia-dependent modification, may be suffi-
cient for participating in the observed CPA. Indeed, a min-
imal overlap was observed between the host proteasomes
and the CPA in the column separation experiments (Fig. 3,
D and E). It is also possible that the chlamydia-secreted fac-
tor(s) may be responsible for specifically binding to certain
host transcription factors such as RFX5 and targeting the
bound molecules to host proteasomes for degradation. This
scenario may explain both the substrate specificity of CPA
and sensitivity of CPA to lactacystin inhibition.
Regardless of the precise mechanisms involved in the
CPA, the fact that we were able to measure the CPA by de-
tecting RFX5 degradation using a cell-free assay in fractions
separated by various types of columns should lead us to pu-
rify and identify the CPA factors encoded by either chlamy-
dia or host alone or both. On a size exclusion column, a
CPA was separated in the fractions following those of 20S
proteasomes (Fig. 3 D), suggesting that the factor(s) is smaller
or forms a smaller complex than the 20S proteasomes. On an
anion exchange column, a CPA was eluted before various
20S proteasome subunits but after an 11S regulatory PA28a
subunit (Fig. 3 C), suggesting that the factor(s) has a pI
higher than 20S proteasomes but lower than the 11S regula-
tory subunit. If a multicomponent or multistep mechanism is
involved in the CPA and the multiple components can be
separated into different fractions as the purification proceeds,
a mix and match approach will be employed to define the
essential factors required for the CPA.
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